CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
CareDx, Inc. (Nasdaq: CDNA) announced new data and product enhancements at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, California. The company showcased advancements in its AlloSeq NGS-based HLA typing solutions for living organ donation and bone marrow transplantation. CareDx also launched an improved QTYPE solution with single bead antigen resolution for faster transplant decisions in deceased donor typing.
The company is hosting a symposium featuring Dr. Annette M. Jackson from Duke University, who will discuss findings on risk haplotypes in pediatric nephrotic syndrome. CareDx representatives will present innovations including a novel HLA haplotyping approach and QTYPE advancements. Key data presentations at ASHI 2024 will highlight the performance of AlloSeq Tx 11, buccal swab performance with AlloSeq Tx 17, and a new approach to HLA haplotyping using LinkPrep reagents with AlloSeq technology.
CareDx, Inc. (Nasdaq: CDNA) ha annunciato nuovi dati e miglioramenti dei prodotti durante il 50° incontro annuale della American Society for Histocompatibility and Immunogenetics (ASHI) ad Anaheim, California. L'azienda ha presentato progressi nelle sue soluzioni di tipizzazione HLA basate su NGS AlloSeq per la donazione di organi viventi e il trapianto di midollo osseo. CareDx ha anche lanciato una versione migliorata della soluzione QTYPE con risoluzione dell'antigeno su singola sfera, per prendere decisioni di trapianto più veloci nella tipizzazione dei donatori deceduti.
L'azienda ospiterà un simposio con la Dott.ssa Annette M. Jackson della Duke University, che discuterà i risultati sui haplotipi di rischio nella sindrome nefrosica pediatrica. I rappresentanti di CareDx presenteranno innovazioni tra cui un nuovo approccio alla tipizzazione HLA e progressi in QTYPE. Le presentazioni chiave di dati ad ASHI 2024 evidenzieranno le performance di AlloSeq Tx 11, le performance del tampone buccale con AlloSeq Tx 17 e un nuovo approccio alla tipizzazione HLA utilizzando i reagenti LinkPrep con la tecnologia AlloSeq.
CareDx, Inc. (Nasdaq: CDNA) anunció nuevos datos y mejoras de productos en la 50ª reunión anual de la American Society for Histocompatibility and Immunogenetics (ASHI) en Anaheim, California. La compañía mostró avances en sus soluciones de tipificación HLA basadas en NGS AlloSeq para la donación de órganos vivos y el trasplante de médula ósea. CareDx también lanzó una solución QTYPE mejorada con resolución de antígeno de una sola perla para decisiones de trasplante más rápidas en la tipificación de donantes fallecidos.
La empresa organizará un simposio con la Dra. Annette M. Jackson de la Universidad de Duke, quien discutirá hallazgos sobre haplotipos de riesgo en el síndrome nefrótico pediátrico. Los representantes de CareDx presentarán innovaciones que incluyen un enfoque novedoso de haplotipificación HLA y avances en QTYPE. Las presentaciones de datos clave en ASHI 2024 destacarán el rendimiento de AlloSeq Tx 11, el rendimiento de hisopos bucales con AlloSeq Tx 17 y un nuevo enfoque a la haplotipificación HLA utilizando reactivos LinkPrep con tecnología AlloSeq.
CareDx, Inc. (Nasdaq: CDNA)는 캘리포니아 애너하임에서 열린 제50회 미국 조직 적합성 및 면역 유전학 회의 (ASHI)에서 새로운 데이터와 제품 개선 사항을 발표했습니다. 이 회사는 생체 장기 기증 및 골수 이식에 대한 AlloSeq NGS 기반 HLA 타이핑 솔루션의 발전을 선보였습니다. CareDx는 또한 사망자 기증자 타이핑에서 더 빠른 이식 결정을 위한 단일 비드 항원 해상도의 개선된 QTYPE 솔루션을 출시했습니다.
이 회사는 듀크 대학교의 Annette M. Jackson 박사를 초청하여 소아 신증후군의 위험 하플로타입에 대한 연구 결과를 논의하는 심포지엄을 주최할 예정입니다. CareDx의 대표들은 새로운 HLA 하플로타입 접근법과 QTYPE의 발전을 포함한 혁신을 발표할 것입니다. ASHI 2024에서의 주요 데이터 발표는 AlloSeq Tx 11의 성능, AlloSeq Tx 17의 구강 면봉 성능, 그리고 AlloSeq 기술을 사용하는 LinkPrep 시약으로 HLA 하플로타입을 설정하는 새로운 접근 방식을 강조할 것입니다.
CareDx, Inc. (Nasdaq: CDNA) a annoncé de nouvelles données et des améliorations de produits lors de la 50ème réunion annuelle de la American Society for Histocompatibility and Immunogenetics (ASHI) à Anaheim, Californie. L'entreprise a présenté des avancées dans ses solutions de typage HLA basées sur NGS AlloSeq pour le don d'organes vivants et la transplantation de moelle osseuse. CareDx a également lancé une solution QTYPE améliorée avec une résolution d'antigène à une seule perle pour des décisions de transplantation plus rapides pour le typage des donneurs décédés.
L'entreprise organise un symposium présenté par Dr. Annette M. Jackson de l'Université de Duke, qui discutera des résultats sur les haplotypes de risque dans le syndrome néphrotique pédiatrique. Les représentants de CareDx présenteront des innovations, y compris une nouvelle approche de typage HLA et des avancées concernant QTYPE. Les présentations de données clés lors d'ASHI 2024 mettront en avant les performances de AlloSeq Tx 11, la performance des écouvillons buccaux avec AlloSeq Tx 17, et une nouvelle approche pour le typage HLA utilisant des réactifs LinkPrep avec la technologie AlloSeq.
CareDx, Inc. (Nasdaq: CDNA) hat auf dem 50. Jahrestreffen der American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, Kalifornien, neue Daten und Produktverbesserungen bekannt gegeben. Das Unternehmen stellte Fortschritte bei seinen AlloSeq NGS-basierten HLA-Typisierungslösungen für die Lebendorganspende und die Knochenmarktransplantation vor. CareDx launchte auch eine verbesserte QTYPE-Lösung mit Einzelperlen-Antigenauflösung für schnellere Transplantationsentscheidungen bei verstorbenen Spendern.
Das Unternehmen veranstaltet ein Symposium mit Dr. Annette M. Jackson von der Duke University, die Ergebnisse zu Risiko-Haplotypen beim pädiatrischen nephrotischen Syndrom besprechen wird. Vertreter von CareDx werden Innovationen präsentieren, einschließlich eines neuartigen HLA-Haplotypisierungsansatzes und Fortschritten bei QTYPE. Wichtige Datenpräsentationen bei ASHI 2024 werden die Leistung von AlloSeq Tx 11, die Leistung von Wangentupfern mit AlloSeq Tx 17 und einen neuen Ansatz zur HLA-Haplotypisierung unter Verwendung von LinkPrep-Reagenzien mit AlloSeq-Technologie hervorheben.
- Launch of improved QTYPE solution with single bead antigen resolution for faster transplant decisions
- Presentation of new data showing 99.9% concordant results and fewer typing ambiguities with AlloSeq Tx 11
- 100% success rate with fragmented buccal DNA using AlloSeq Tx 17 hybrid capture method
- Introduction of a novel approach to HLA haplotyping using LinkPrep reagents with AlloSeq technology
- None.
New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing
CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing
The latest advances across CareDx’s portfolio of AlloSeq™ NGS-based HLA typing solutions are being featured demonstrating its clinical utility in living organ donation typing and bone marrow transplantation. CareDx is also launching its newly improved QTYPE® solution which now includes single bead antigen resolution to facilitate virtual crossmatching in deceased donor typing for faster transplant decisions.
“We are committed to delivering the most advanced HLA typing solutions to optimally support pre-transplant recipient and donor matching in both solid organ and stem cell transplantation,” said John W. Hanna, CareDx President and CEO. “We’re excited to share our latest product innovations and supporting data at this year’s ASHI meeting.”
CareDx is hosting a symposium at the meeting to share its latest product advancements. Annette M. Jackson, PhD, F(ACHI), from Duke University, a leading expert in the field of clinical transplant immunology, will speak at the symposium about her lab’s latest findings identifying risk haplotypes in pediatric nephrotic syndrome. CareDx speakers, Curt Lind, PhD, VP and Head of Lab Products R&D, and Beata Kmiec, PhD, Senior Product Manager, will share CareDx’s latest product innovations including a novel approach to HLA haplotyping and the latest advancement to QTYPE, a real-time PCR solution that now combines high coverage redundancy and single antigen resolution on a single run.
“Our clinical research team at Duke is grateful to partner with CareDx to validate the discovery of new HLA associated diseases such as pediatric steroid sensitive nephrotic syndrome, a rare but serious condition that can lead to kidney failure,” said Annette M. Jackson, PhD, F(ACHI), Associate Professor, Departments of Surgery & Immunology Chief, Clinical Transplantation Immunology Research Director, Clinical Transplantation Immunology Laboratory Duke University.
Key data to be presented at ASHI 2024:
-
Validation of AlloSeq Tx 11, NGS Typing of 11 Classical HLA Loci. Morris T, Willis A, Kmiec B, et al. This study shows that the addition of new probes in AlloSeqTx 11 increases the sequencing coverage of Class II loci, for
99.9% concordant results leading to fewer typing ambiguities. -
Assessment of Buccal Swab Performance Utilizing Hybrid Capture HLA Typing. Morris T, Willis A, Kmiec B, et al. This study showed that using AlloSeq Tx 17 hybrid capture method had a
100% success rate with fragmented buccal DNA, compared to43% with alternate methods using long range PCR. - Haplotyping in 3-D – Long-distance phasing of short NGS reads – a novel approach to HLA haplotyping. Lind C, Morris T, Willis A, et al. This study showed that using LinkPrep™ reagents from Dovetail Genomics paired with AlloSeq Tx hybrid capture technology and AlloSeq Assign successfully enable both high resolution genotyping and haplotyping without the need for family studies.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloSeq, QTYPE, and other CareDx products and statements regarding the data to be presented at the annual American Society for Histocompatibility and Immunogenetics meeting. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSeq, QTYPE, and other CareDx products; risks that the data to be presented at the ASHI may not follow the agenda as stated in this press release; risks that the findings in the studies supporting the data may be inaccurate; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021441408/en/
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
Source: CareDx, Inc.
FAQ
What new product did CareDx (CDNA) introduce at the ASHI 2024 meeting?
What were the key findings presented for AlloSeq Tx 11 at ASHI 2024?
How did AlloSeq Tx 17 perform in buccal swab testing at ASHI 2024?
What new approach to HLA haplotyping did CareDx (CDNA) present at ASHI 2024?
